Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.55 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | ICMT | O60725 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637290 | 0.84 | CXCR4 (0.63) | CXCR4FPR2RORCNAMPTHTT | |
| SCHEMBL2694469 | 0.82 | CXCR4 (0.76) | CXCR4FPR2RORCADRB1ADRB3 | |
| SCHEMBL1637267 | 0.80 | CXCR4 (0.55) | CXCR4FPR2HTT | |
| SCHEMBL1636365 | 0.79 | CXCR4 (0.68) | CXCR4FPR2RORC | |
| SCHEMBL1206373 | 0.79 | CXCR4 (0.69) | CXCR4NAMPT | |
| SCHEMBL4953981 | 0.79 | CXCR4 (0.60) | CXCR4TAAR1 | |
| SCHEMBL12507647 | 0.78 | CXCR4 (0.68) | CXCR4NAMPT | |
| SCHEMBL12894415 | 0.78 | CXCR4 (0.55) | CXCR4FPR2RORCNAMPTHTT | |
| SCHEMBL1638175 | 0.78 | CXCR4 (0.59) | CXCR4TAAR1 | |
| SCHEMBL1637139 | 0.77 | CXCR4 (0.60) | CXCR4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | CXCR4 86/4885FPR2 152/4885ICMT 3170/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | CXCR4 100/4885FPR2 137/4885ICMT 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.